Cancer and the blood-brain barrier: 'Trojan horses' for courses?
The blood-brain barrier (BBB) limits the bioavailability of most bioactive molecules and drugs in the CNS, leaving clinicians with only a few options for pharmacotherapy. In this issue Regina et al. demonstrate that a 'Trojan horse' drug conjugate, acting as a substrate of a physiological BBB receptor that facilitates transcytosis, significantly improves drug transport into the CNS. Specifically, the low-density lipoprotein receptor-related protein (LRP) is used to carry a conjugate of paclitaxel and Angiopep-2, an aprotinin-derived peptide, across the BBB. Interestingly, in its conjugated form paclitaxel circumvents the efflux pumps at the BBB but still retains its activity against microtubules. Importantly, the authors were able to demonstrate improved therapeutic efficacy of this approach in orthotopic models of primary and metastatic brain cancer. This proof-of-principle study thus represents a milestone for drug delivery across the BBB but also a starting point for studies exploring wider applicability and potential limitations of the approach.
Mazza
M
M
School of Pharmacy, University of London, London, UK.
Uchegbu
I F
IF
Schätzlein
A G
AG
D000818:Animals; D001692:Biological Transport / Q000502:physiology*; D001812:Blood-Brain Barrier / Q000378:metabolism / Q000502:physiology*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D026503:Low Density Lipoprotein Receptor-Related Protein-1 / Q000008:administration & dosage* / Q000378:metabolism; D009423:Nervous System Neoplasms / Q000378:metabolism*; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics
D004337:Drug Carriers; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D017239:Paclitaxel